Drug Search Results
More Filters [+]

GS-4528

Alternative Names: GS-4528, GS 4528, GS4528
Latest Update: 2023-06-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GS-4528

Countries in Clinic: Canada

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GS-US-616-6291

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-12-01

39%

Recent News Events

Date

Type

Title